Abstract
Many men with newly diagnosed prostate cancer choose not to undergo curative treatment, including patients who cannot be helped by local curative therapies (especially those with metastatic disease) and patients with clinically localized disease who opt for expectant management or noncurative treatments such as androgen ablation. This article reviews the selection of patients for these noncurative approaches, strategies for clinical monitoring, the choices of intervention therapies upon progression, and when to start these therapies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 687-702 |
| Number of pages | 16 |
| Journal | Urologic Clinics of North America |
| Volume | 30 |
| Issue number | 4 |
| DOIs | |
| State | Published - Nov 2003 |
Fingerprint
ASJC Scopus subject areas
- Urology
Cite this
Follow-up of conservatively managed prostate cancer Watchful waiting and primary hormonal therapy. / Messing, Edward M.; Thompson, Ian.
In: Urologic Clinics of North America, Vol. 30, No. 4, 11.2003, p. 687-702.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Follow-up of conservatively managed prostate cancer Watchful waiting and primary hormonal therapy
AU - Messing, Edward M.
AU - Thompson, Ian
PY - 2003/11
Y1 - 2003/11
N2 - Many men with newly diagnosed prostate cancer choose not to undergo curative treatment, including patients who cannot be helped by local curative therapies (especially those with metastatic disease) and patients with clinically localized disease who opt for expectant management or noncurative treatments such as androgen ablation. This article reviews the selection of patients for these noncurative approaches, strategies for clinical monitoring, the choices of intervention therapies upon progression, and when to start these therapies.
AB - Many men with newly diagnosed prostate cancer choose not to undergo curative treatment, including patients who cannot be helped by local curative therapies (especially those with metastatic disease) and patients with clinically localized disease who opt for expectant management or noncurative treatments such as androgen ablation. This article reviews the selection of patients for these noncurative approaches, strategies for clinical monitoring, the choices of intervention therapies upon progression, and when to start these therapies.
UR - http://www.scopus.com/inward/record.url?scp=0344011550&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0344011550&partnerID=8YFLogxK
U2 - 10.1016/S0094-0143(03)00050-8
DO - 10.1016/S0094-0143(03)00050-8
M3 - Article
C2 - 14680308
AN - SCOPUS:0344011550
VL - 30
SP - 687
EP - 702
JO - Urologic Clinics of North America
JF - Urologic Clinics of North America
SN - 0094-0143
IS - 4
ER -